Use of rapid molecular tuberculosis diagnostics across Brazil's incarcerated population

- 3 Elinor B. Fajer¹, Fernanda Dockhorn Costa², Daniele Maria Pelissari², Fredi Alexander Diaz
- 4 Quijano³, Artemir Coelho de Brito², Eunice Atsuko Totumi Cunha⁴, Julio Croda^{5,6,7}, Jason R.
- 5 Andrews¹, Katharine S. Walter¹
- 7 1. Stanford University School of Medicine, Stanford, CA, United States
- 8 2. National Tuberculosis Control Program, Brasília, DF, Brazil
- 9 3. Department of Epidemiology, School of Public Health, University of São Paulo, São Paulo,
- 10 SP, Brazil

1

2

6

15

17

22

24

- 4. Central Laboratory of Public Health, Campo Grande, Brazil
- 5. Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil
- 13 6. Oswaldo Cruz Foundation, Campo Grande, Brazil
- 7. Yale School of Public Health, New Haven, CT, United States
- Running Head: TB diagnostic use among prison populations
- 18 Article Word Count: 2433
- 19 References: 30
- 20 Tables: 2
- 21 Figures: 4
- 23 Keywords: tuberculosis; prisons; diagnostic gap; Xpert MTB/RIF
- 25 Correspondence:
- 26 Elinor B. Fajer
- 27 Stanford University
- 28 450 Serra Mall
- 29 Stanford, CA, USA, 94305
- 30 Email: efajer@stanford.edu

32 Abstract (200 words) 33 **Background**: Incarcerated individuals in Brazil are at high-risk of tuberculosis (TB), but their 34 access to World Health Organization recommended diagnostics is poorly understood. 35 **Methods**: We conducted a retrospective cross-sectional study of newly diagnosed TB cases in 36 Brazil's notifiable disease registry, which includes information on diagnostic tests performed, 37 from January 2015 through December 2018. We quantified reported use of TB diagnostics across 38 incarcerated and non-incarcerated populations and tested for municipality-level factors 39 associated with diagnostic usage among the incarcerated population with generalized linear 40 regression. **Results**: Between 2015 and 2018, 258,014 individuals were newly diagnosed with TB, including 41 42 27,400 (10.6%) incarcerated individuals. Among these, 27.5% had an Xpert MTB/RIF test 43 reported; 71.5% had sputum smear; 34.1% had culture; 70.9% had chest radiography. Xpert MTB/RIF use was greater among incarcerated than non-incarcerated individuals (36.2% vs 44 45 26.5%, p<0.001). However, we found spatial heterogeneity in state-level use of both Xpert MTB/RIF (range: 4.7-72.4% cases diagnosed) and chest radiography (range: 11.7-88.4%) in 46 prisons. We identified seven municipalities with large incarcerated populations (>5000) with 47 48 rates of Xpert MTB/RIF usage below the national average in incarcerated individuals. **Conclusion**: Prioritizing expansion of rapid molecular diagnostics in prisons, particularly in 49 50 regions with limited current usage of molecular diagnostics, will be an essential component of 51 TB control.

52

INTRODUCTION

Tuberculosis (TB) is one of the leading causes of death by infectious disease worldwide¹. However, there remains a large population of undiagnosed TB cases, which the COVID-19 pandemic has further expanded¹. In 2020, of the estimated 9.9 million globally incident TB cases, only 5.8 million cases were reported¹. Reducing this diagnostic gap through early diagnosis of disease and rapid detection of drug resistance is critical for both managing individual outcomes and for preventing onwards transmission of TB¹⁻³.

As part of the End TB Strategy, the World Health Organization (WHO) recommends that all individuals with symptoms of TB should have access to WHO-endorsed molecular rapid diagnostic tests⁴. Rapid molecular diagnostic tests such as Xpert MTB/RIF have high sensitivity (89%) and specificity (99%) in detecting *M. tuberculosis* when compared to a microbiological reference standard and a low limit of detection^{5,6}, enabling detection of *M. tuberculosis* in paucibacillary samples. Further, automated molecular diagnostics like Xpert MTB/RIF do not require biosafety level three facilities, extensive laboratory capacity, or long follow-up periods, as do many other diagnostics. However, in many high-incidence countries, sputum smear microscopy remains the most used diagnostic test, and culture remains the gold standard for TB positivity.

Expanding access to rapid molecular TB diagnostics is an urgent priority for vulnerable populations such as incarcerated individuals, who globally have a TB incidence ten times that of the general population⁷. In the Americas, TB notifications are increasingly concentrated within prisons^{8,9}, including in Brazil, where 12.2% of the country's notified TB cases occurred among incarcerated individuals in 2019¹¹. The conditions of detention put individuals at high risk of TB infection and often reduce their contact with healthcare systems, resulting in a lower probability of early diagnosis and treatment^{9,12}. Higher TB levels across incarcerated populations not only affect these groups of people directly, but also have impacts at the population level due to amplifying factors such as spillover^{13–15}.

Early diagnosis and treatment is critical for reducing the burden of TB in prisons, and the speed, accessibility, and cost effectiveness of Xpert MTB/RIF makes it especially suitable in prison settings¹⁶. Modeling studies have found that active screenings with Xpert MTB/RIF can significantly reduce the burden of TB among incarcerated populations^{13,17–19}. While the Brazil

National Tuberculosis Program recently endorsed the use of Xpert MTB/RIF, the usage of rapid molecular diagnostics in prisons has not yet been explored. Additionally, as studies have supported chest radiography use for mass screenings in prison settings¹⁷, the usage of this diagnostic across Brazil's incarcerated population is also of interest.

Here, we analyzed Brazil's national notifiable disease registry to quantify the use of Xpert MTB/RIF and chest radiography across Brazil's incarcerated population and to identify critical gaps in the usage of recommended diagnostics.

METHODS

Study design and data sources

We conducted a retrospective cohort study of newly diagnosed tuberculosis cases reported to Brazil's national notifiable disease system, Sistema de Informação de Agravos de Notificação (SINAN), from January 2015 through December 2018. In Brazil, individual tuberculosis diagnoses are compulsorily reported in SINAN²⁰. SINAN includes patient clinical and sociodemographic information, incarceration status at the time of TB notification, TB diagnostic test results, and TB treatment outcomes. We restricted the study period to between 2015 and 2018 as Xpert MTB/RIF implementation began in late 2014, and data for years following 2018 were incomplete at the time of the study. We excluded cases with unknown incarceration status or of patients below 18 years of age, as they make up a small proportion of the incarcerated population in Brazil.

Patients may receive more than one diagnostic test to confirm their TB diagnosis. SINAN reports diagnostic results by testing modality, including Xpert MTB/RIF, chest radiography, sputum smear, and culture. Xpert MTB/RIF test outcomes are reported as *M. tuberculosis* detected, sensitive to Rifampicin; *M. tuberculosis* detected, resistant to Rifampicin; *M. tuberculosis* not detected; inconclusive test; or not performed. Xpert MTB/RIF G4 was primarily used during our study period, though Brazil introduced Xpert MTB/RIF Ultra across the country's laboratory network in 2019. Chest radiography test outcomes are reported as suspect, normal, other pathology, or not performed; sputum smear outcomes are reported as positive, negative, not performed, or not applicable; and culture outcomes are reported as positive,

negative, in-progress, or not performed. For each individual diagnostic test, we classified individuals with positive, negative, or in-progress reported results as having received that test (test usage), and individuals with tests marked not performed or missing information as having not received that diagnostic test (no test usage). At the municipality level, we defined test use as the proportion of cases diagnosed with each respective diagnostic tool.

In addition to the individual level variables extracted from SINAN, we collected municipality-level covariates, including average per capita household income and GINI coefficient, from the Human Development Atlas²¹. The Human Development Atlas collects data each decade; therefore, we used data from the most recent report (2010). We obtained incarcerated population size by municipality from Brazil's National Prison Information Survey²² and data for total municipality population density from the Brazilian Institute of Geography and Statistics²³.

Statistical Analysis

Data analysis was conducted using R (version 3.6.3) and R Studio (version 1.3.1093). We first compared the proportions of patients diagnosed with Xpert MTB/RIF, chest radiography, sputum smear, and culture between incarcerated and non-incarcerated populations with two-proportion z-tests. A multiple samples proportions test was performed to assess the increasing trend in Xpert MTB/RIF use over the study period.

We calculated use of the four testing modalities at state and municipality levels based on individual-level data from SINAN and the location of patients' diagnoses. Chi-square tests for equality of proportions were run to assess the significance of state-level diagnostic use heterogeneity. An 'empty' multilevel regression²⁴ was run with state or municipality random effects respectively and no other predictor variables. These models were used to estimate the intraclass correlation coefficients (ICC) for municipality and state-level clustering, a measure of the proportion of total variability as determined by cluster membership.

We used mixed effects binomial regression to identify covariates associated with use of Xpert MTB/RIF and chest radiography among the incarcerated population. We included municipality population density, GINI coefficient, incarcerated population size, average per capita household income, and year (2015 through 2018) as fixed effects, and municipality of TB

diagnosis as a random effect. The population density, incarcerated population size, and average per capita household income variables were on a log scale. The GINI coefficient was rescaled by a factor of ten for to optimize model fitting.

We investigated gaps in diagnostic use for all Brazil municipalities with incarcerated populations of at least 5000 individuals and with at least 5 TB cases from 2015 through 2018.

Ethics Statement

This study was approved by the Institutional Review Board at Stanford University (Protocol #50466).

RESULTS

In Brazil between 2015 and 2018, there were 284,415 newly diagnosed TB cases reported to Brazil's Notifiable Diseases Information System (SINAN), of which 258,014 were among patients over 18 years of age and with information on incarceration status. Of these notified cases, 10.6% (27,400 of 258,014 cases) occurred among incarcerated individuals and 89.4% (230,614 of 258,014) were among the general population. We found overall Xpert MTB/RIF use of 27.5% (70,988 of 258,014), chest radiography use of 70.9% (183,058 of 258,014), sputum smear use of 71.5% (184,509 of 258,014), and culture use of 34.1% (87,905 of 258,014), with significant overlap in populations receiving different diagnostic tests (Fig. 1). TB patients received a mean of 2.04 diagnostic tests, with the greatest overlap of 27.4% of patients receiving both chest radiography and sputum smear.

Between 2015 and 2018, use of Xpert MTB/RIF and chest radiography diagnostic testing differed significantly between Brazil's incarcerated and non-incarcerated populations (Fig. 2). Use of Xpert MTB/RIF for incarcerated individuals was greater than that for non-incarcerated individuals (36.2% vs 26.5%, p-value<0.001 each year and overall). Xpert MTB/RIF use in prison settings increased over the four years (p-value<0.001 for a positive linear trend in Xpert MTB/RIF use). Chest radiography use was consistently lower for incarcerated individuals than for non-incarcerated individuals (41.6% vs 74.4%, p-value<0.001 each year and overall).

Across Brazil's 26 states and one federal district, we found significant heterogeneity in usage in prisons for both Xpert MTB/RIF (X-squared=2717.3, df=26, p<0.001) and chest radiography (X-squared=9039.7, df=26, p<0.001) (Fig. 3). Diagnosis with Xpert MTB/RIF ranged from 4.7% and 4.9% in Pará and Mato Grosso, to 64.5% and 72.4% in Goiás and Amapá, respectively. Similarly, diagnosis with chest radiography ranged from 11.7% and 18.9% in São Paulo and Amapá, to 84.5% and 88.4% in Rio De Janeiro and Espírito Santo, respectively.

Brazil is further divided from the state level into 5,570 municipalities, of which 1,514 contain at least one prison, and 1,235 had at least one TB case from its incarcerated population reported to SINAN between 2015 to 2018. Primary healthcare in Brazil, including healthcare within prisons, is provided by municipalities²⁵. We found that 21.3% and 52.1% of variation in Xpert MTB/RIF use, as measured by intraclass correlation coefficients, can be attributed to a patient's state and municipality, respectively (Fig. 3c). Similarly, 22.8% and 54.9% of variation in chest radiography use among incarcerated populations can be attributed to a patient's state and municipality, respectively.

To identify other potential predictors of diagnostic use among the incarcerated population, we fit binomial regression models for both diagnostics (Table 1). We found that Xpert MTB/RIF use was greater in 2017 (OR:1.55, CI:1.42-1.69) and 2018 (OR:2.23, CI:2.03-2.44, p<0.001) compared to 2015. A greater municipality incarcerated population size was associated with greater use of Xpert MTB/RIF (OR:1.76, CI:1.49-2.08, p<0.001), though average per capita income, GINI coefficient, and population density were not significantly correlated with Xpert MTB/RIF use. Additionally, we found that GINI coefficient and per capita income were significantly positively associated with chest radiography use, while incarcerated population size was negatively associated with chest radiography use.

To identify specific gaps in Xpert MTB/RIF and chest radiography usage across Brazil's incarcerated population, we further examined municipalities with incarcerated populations of at least 5000 individuals and with at least 5 diagnosed TB cases between 2015-2018 (Fig. 4, Table 2). Of these 26 municipalities, seven reported that less than the national average of 36.2% of incarcerated patients were diagnosed with Xpert MTB/RIF, and 18 reported that less than the national average of 41.6% of incarcerated patients diagnosed were with chest radiography.

DISCUSSION

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

We found that the use of TB diagnostic tests differs significantly between the incarcerated and general populations in Brazil. The use of Xpert MTB/RIF was greater among the incarcerated population and expanded in 2017 and 2018 compared to 2015, as expected with the gradual implementation of this test across prisons. Further, we found that diagnosis with Xpert MTB/RIF and chest radiography is largely determined by a patient's state and municipality at time of diagnosis, reflecting the varying TB programs and control efforts organized by Brazil's municipalities. Finally, we identified several gaps in which municipalities with large prison populations had very limited use of Xpert MTB/RIF and/or chest radiography. As a significant and increasing proportion of TB notifications in Brazil occur among the incarcerated population⁹, and as prisons can amplify community TB epidemics^{13–15}, targeting prisons for TB control efforts can substantially impact Brazil's overall TB incidence. Given the high accuracy of Xpert MTB/RIF in diagnosing TB and its effectiveness within prison settings^{6,16,26,27}, ensuring equitable access to this diagnostic across Brazil's incarcerated population is critical. Our findings suggest that efforts to expand Xpert MTB/RIF availability in prisons have been effective, as a greater proportion of incarcerated versus non-incarcerated individuals were diagnosed with this test, and as the proportion diagnosed increased through the study period. Yet our observation of significant spatial heterogeneity in Xpert MTB/RIF use across Brazil's prisons indicates that a large population in Brazil may not currently have access to this tool based on where they live. Thus, targeting the specific municipalities identified as having large incarcerated populations and limited Xpert MTB/RIF use should be a focus of continued Xpert MTB/RIF expansion and overall TB control efforts as addressing issues in these settings could help to further limit TB incidence in and beyond prison settings. Reducing the TB diagnostic gap remains a global challenge, and efforts to expand access to Xpert MTB/RIF testing in prisons and across healthcare systems globally will be critical to achieve the WHO End TB Strategy of an 80% decrease in new cases by 2030⁴. Some countries have reported rapid expansion of Xpert MTB/RIF. For example, in Uzbekistan, Xpert MTB/RIF coverage increased from 24% in 2018 to 46% in 2019²⁸, and in El Salvador, the use of Xpert MTB/RIF testing as part of a package of TB diagnostic interventions tripled incarcerated TB notifications in five years²⁹. However, barriers to equitable diagnostic access remain, such as diagnostic machine service coordination issues³⁰, and further research will be necessary to

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

identify diagnostic gaps and policy solutions. Our findings of significant spatial heterogeneity in Xpert MTB/RIF usage across Brazil and by incarceration status highlight the importance of understanding diagnostic availability for other national TB control programs. There are several limitations to this study. First, availability of specific diagnostic tests across Brazil's diagnostic facilities is not centrally reported, and individual access to diagnostic tests cannot be ascertained from SINAN. We investigated the usage of different diagnostics among confirmed cases, which may reflect availability of diagnostics in a particular setting, functionality, and selection by healthcare providers. However, we were unable to investigate how widely Xpert MTB/RIF is used among all individuals with suspected TB, and hence cannot report usage for individuals who did not actually receive a confirmed diagnosis. Another limitation was the use of 2010 socioeconomic indicators in the binomial regression. Though these values have been improving over time, the 2015 economic crisis could have variably influenced socioeconomic factors across municipalities; as a census has not been conducted since, the 2010 data still provide a strong estimate. Third, we excluded cases where the incarceration status was not reported. This represents under 3.2% of total cases (9,086 of 284,415), so we have confidence that excluding diagnostic usage data for this population does not significantly impact our results. Finally, our study focuses on years preceding the COVID-19 pandemic. Understanding the effect of COVID-19 on widening TB diagnostic gaps within and outside prisons is critical for TB control programs¹. Ultimately, to achieve the WHO End TB goals, targeted expansion of rapid molecular diagnostics for incarcerated populations and regions with limited diagnostic usage will be essential and could reduce significant diagnostic gaps. Funding: National Institutes of Health grant R01 AI130058 (JRA) and R01 AI149620 (JRA and JC). EBF, KSW, JRA, and JC conceived of the study. EBF analyzed data and made data visualizations. KSW and JC acquired data. All authors contributed to paper revisions and approved of the final version.

REFERENCES

271

- 273 1. Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021. Licence:
- 274 CC BY-NC-SA 3.0 IGO.
- 275 2. Impact of the COVID-19 pandemic on TB detection and mortality in 2020. Accessed
- August 12, 2021. https://www.who.int/publications/m/item/impact-of-the-covid-19-
- pandemic-on-tb-detection-and-mortality-in-2020
- 278 3. Pai M. Diagnostics for tuberculosis: what test developers want to know.
- 279 http://dx.doi.org/101586/erm1316. 2014;13(4):311-314. doi:10.1586/ERM.13.16
- 280 4. WHO operational handbook on tuberculosis. Module 3: Diagnosis Rapid diagnostics for
- tuberculosis detection 2021 update. Accessed August 12, 2021.
- 282 https://www.who.int/publications/i/item/9789240030589
- 283 5. Marlowe EM, et al. Notes: Evaluation of the Cepheid Xpert MTB/RIF Assay for Direct
- Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens. *J Clin*
- 285 *Microbiol.* 2011;49(4):1621. doi:10.1128/JCM.02214-10
- 286 6. Steingart KR, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin
- resistance in adults. *Cochrane Database Syst Rev.* 2013;18(1):77-78.
- 288 doi:10.1002/14651858.CD009593.PUB2
- 289 7. Cords O, et al. Incidence and prevalence of tuberculosis in incarcerated populations: a
- systematic review and meta-analysis. *Lancet Public Heal*. 2021;6(5). doi:10.1016/S2468-
- 291 2667(21)00025-6
- 8. Sequera VG, et al. Increased incarceration rates drive growing tuberculosis burden in
- prisons and jeopardize overall tuberculosis control in Paraguay. Sci Reports 2020 101.
- 294 2020;10(1):1-7. doi:10.1038/s41598-020-77504-1
- 295 9. Walter KS, et al. The escalating tuberculosis crisis in central and South American prisons.
- 296 *Lancet*. 2021;397(10284):1591-1596. doi:10.1016/S0140-6736(20)32578-2
- 297 10. Pelissari DM, Diaz-Quijano FA. Impact of incarceration on tuberculosis incidence and its
- interaction with income distribution inequality in Brazil. *Trans R Soc Trop Med Hyg.*
- 299 2020;114(1):23-30. doi:10.1093/TRSTMH/TRZ088
- 300 11. TabNet Win32 3.0: TUBERCULOSE Casos confirmados notificados no Sistema de
- 301 Informação de Agravos de Notificação Brasil. Accessed October 3, 2021.

- 302 http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sinannet/cnv/tubercbr.def
- 303 12. Reyes K, Amores JC. Barriers of Early TB Diagnosis among the Poor in Highly
- 304 Urbanized Areas in the Philippines. Published online 2014. Accessed July 19, 2021.
- 305 https://www.econstor.eu/handle/10419/126984
- 306 13. Mabud TS, et al. Evaluating strategies for control of tuberculosis in prisons and
- prevention of spillover into communities: An observational and modeling study from
- 308 Brazil. *PLoS Med.* 2019;16(1). doi:10.1371/JOURNAL.PMED.1002737
- Walter KS, et al. Genomic evidence for prisons as amplifiers of community tuberculosis
- epidemics. *medRxiv*. Published online June 24, 2021:2021.06.22.21259360.
- 311 doi:10.1101/2021.06.22.21259360
- 312 15. Baussano I, et al. Tuberculosis Incidence in Prisons: A Systematic Review. *PLOS Med*.
- 313 2010;7(12):e1000381. doi:10.1371/JOURNAL.PMED.1000381
- 314 16. Dara M, et al. Tuberculosis control in prisons: current situation and research gaps. *Int J*
- 315 *Infect Dis.* 2015;32:111-117. doi:10.1016/J.IJID.2014.12.029
- 316 17. Santos A da S, et al. Yield, Efficiency, and Costs of Mass Screening Algorithms for
- Tuberculosis in Brazilian Prisons. *Clin Infect Dis.* 2021;72(5):771-777.
- 318 doi:10.1093/CID/CIAA135
- 319 18. Pelissari DM, et al. Prevalence and screening of active tuberculosis in a prison in the
- 320 South of Brazil. *Int J Tuberc Lung Dis.* 2018;22(10):1166-1171.
- 321 doi:10.5588/JJTLD.17.0526
- 322 19. Fournet N, et al. Development and evaluation of tuberculosis screening scores in Brazilian
- prisons. *Public Health*. 2006;120(10):976-983. doi:10.1016/J.PUHE.2006.06.004
- 324 20. Brasil Ministério da Saúde. Manual de Recomendações para o Controle da Tuberculose no
- Brasil. Accessed July 19, 2021. www.saude.gov.br/
- 326 21. Atlas Brasil. Accessed July 19, 2021. http://www.atlasbrasil.org.br/
- 327 22. Infopen National Prison Information Survey Datasets Ministry of Justice and Public
- Security. Accessed July 19, 2021. http://dados.mj.gov.br/dataset/infopen-levantamento-
- 329 nacional-de-informacoes-penitenciarias
- 330 23. Population | IBGE. Accessed July 19, 2021.
- https://www.ibge.gov.br/en/statistics/social/population.html
- 332 24. Sommet N, Morselli D. Keep Calm and Learn Multilevel Logistic Modeling: A Simplified

333 Three-Step Procedure Using Stata, R, Mplus, and SPSS. *Int Rev Soc Psychol*. 334 2017;30(1):203-218. doi:10.5334/IRSP.90 335 25. Brazil | Commonwealth Fund. Accessed August 12, 2021. 336 https://www.commonwealthfund.org/international-health-policy-center/countries/brazil 337 26. Marine E, et al. Improving tuberculosis management in prisons: Impact of a rapid 338 molecular point-of-care test. J Infect. 2021;82(2):235-239. 339 doi:10.1016/J.JINF.2020.11.042 340 27. Chang K, et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance 341 with Xpert MTB/RIF assay: A meta-analysis. J Infect. 2012;64(6):580-588. 342 doi:10.1016/J.JINF.2012.02.012 343 28. Turaev L, et al. Universal Access to Xpert MTB/RIF Testing for Diagnosis of 344 Tuberculosis in Uzbekistan: How Well Are We Doing? Int J Environ Res Public Heal 345 2021, Vol 18, Page 2915. 2021;18(6):2915. doi:10.3390/IJERPH18062915 29. 346 Ayala G, et al. Trends in tuberculosis notification and treatment outcomes in prisons: a 347 country-wide assessment in El Salvador from 2009-2014 Investigación original / Original 348 research Suggested citation Trends in tuberculosis notification and treatment outcomes in 349 prisons: a country-wide assessment in El. Rev Panam Salud Publica. 39(1):2016. 350 30. Moyenga I, et al. The impact of Xpert® MTB/RIF depends on service coordination: 351 Experience in Burkina Faso. Int J Tuberc Lung Dis. 2015;19(3):285-287. 352 doi:10.5588/IJTLD.14.0629 353 354

Table 1. Multivariable regression for use of Xpert MTB/RIF and chest radiography with municipality random effects. The odds ratios (OR), 95% confidence intervals (CI), and p-values are listed for each predictor, with significantly associated covariates in bold.

		Access to Xpert MTB/RIF			Access to Chest Radiography		
Predictors		OR	95% CI	p	OR	95% CI	p
Covariate							
	Population Density*	1.04	0.92 - 1.17	0.542	1.01	0.90 - 1.12	0.919
	Gini Coefficient**	0.98	0.72 - 1.35	0.913	1.50	1.12 - 2.03	0.007
	Incarcerated Population	1.76	1.49 - 2.08	< 0.001	0.45	0.39 - 0.52	< 0.001
	Size*						
	Average per Capita	1.40	0.88 - 2.22	0.156	3.33	2.10 - 5.30	< 0.001
	Income*						
Year							
	2015	Ref			Ref		
	2016	0.97	0.88 - 1.06	0.458	0.89	0.80 - 0.99	0.026
	2017	1.55	1.42 - 1.69	< 0.001	0.97	0.88 - 1.07	0.565
	2018	2.23	2.03 - 2.44	< 0.001	1.17	1.06 - 1.29	0.002
*log-scale							

^{*}log-scale

360

361

356

357

^{**}rescaled by a factor of 10

Table 2. Use of TB diagnostics among the incarcerated populations in selected municipalities. We selected municipalities with incarcerated populations of at least 5000 and with at least 5 TB incarcerated TB diagnoses between 2015 to 2018. Table columns indicate the incarcerated population size and TB diagnoses for each municipality, as well as the percent of TB cases diagnosed with Xpert MTB/RIF or chest radiography, from 2015-2018.

Region	State	Municipality	Incarcerated	Incarcerated TB	% Diagnosed	% Diagnosed with Chest	
			Population Size,	Diagnoses, 2015-	with Xpert		
			2018	2018	MTB/RIF	Radiography	
North	RO	Porto Velho	6475	265	55.1	37.7	
	AM	Manaus	7748	311	53.4	39.5	
	PA	Santa Izabel Do Pará	5439	339	1.5	40.4	
Northeast	MA	São Luís	5462	305	59.3	86.9	
	CE	Itaitinga	9670	569	38.0	24.4	
	PB	João Pessoa	5203	214	53.1	33.9	
	PE	Recife	6409	560	34.1	20.0	
	AL	Maceió	7619	107	67.3	25.2	
	BA	Salvador	5001	209	67.9	31.1	
Southeast	MG	Ribeirão Das	9522	34	0.0	82.4	
		Neves					
		São Joaquim De	5278	17	5.9	47.1	
		Bicas					
	ES	Vila Velha	7958	18	16.7	72.2	
	RJ	Rio De Janeiro	36243	3417	13.8	83.8	
	SP	Bauru	6601	347	65.1	16.4	
		Franco Da Rocha	9804	317	12.3	14.8	
		Guarulhos	7457	380	54.5	3.9	
		Hortolândia	6741	307	64.2	5.2	
		Lavínia	6291	297	63.0	2.0	
		Mirandópolis	5404	201	60.7	13.9	
		São Paulo	15252	914	65.0	21.0	
		Tremembé	6837	187	62.6	2.1	
South	RS	Charqueadas	5142	240	67.1	25.0	
		Porto Alegre	6204	614	57.8	92.0	
Central-	MS	Campo Grande	5572	435	37.9	49.0	

West	GO	Aparecida De	6440	268	87.3	6.0
		Goiânia				
	DF	Brasília	16359	138	60.9	51.4

Figure legends:

Figure 1: Venn diagram of TB diagnostic use. Percentage of newly diagnosed TB cases with diagnostic test results reported for 1) Xpert MTB/RIF, 2) Chest Radiography, 3) Smear, and 4) Culture. Numbers in overlaps indicate individuals who received multiple diagnostic tests.




Figure 2: Tuberculosis **diagnostic test use in Brazil.** Proportions of incarcerated (light blue) and non-incarcerated (dark blue) individuals diagnosed between 2015-2018 by A) Xpert MTB/RIF, B) chest radiography, C) smear, and D) culture.

378





Figure 3: Spatial heterogeneity in the use of Xpert MTB/RIF and chest radiography among the incarcerated population. A) Map of Brazilian states showing the percent of incarcerated individuals diagnosed with Xpert MTB/RIF between 2015 to 2018. Darker colors represent greater diagnostic use. B) Map of Brazilian states showing the percent of incarcerated individuals diagnosed with chest radiography between 2015 to 2018. C) The variance in use of Xpert MTB/RIF and chest radiography attributed to state (dark blue) and municipality (light blue) random effects as measured by the intraclass correlation coefficient (ICC).






Figure 4: Gaps use of Xpert MTB/RIF and chest radiography in the incarcerated population. A) The proportion of incarcerated individuals in each municipality who were diagnosed without Xpert MTB/RIF, colored by region. Longer bars suggest a greater gap in diagnostic use. B) The proportion of incarcerated individuals in each municipality who were diagnosed without chest radiography, colored by region. C) The 26 municipalities labeled within a map of Brazil, colored by region.

